vokanamet
janssen-cilag international nv - canagliflozin, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - vokanamet huwa indikat f'adulti ta '18-il sena u akbar b'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku:f'pazjenti li mhumiex kontrollati sew fuq xieraq bl-felħu dożi ta' metformin alonein pazjenti fuq xieraq bl-felħu dożi ta 'metformin flimkien ma' oħrajn li jbaxxu glucose-prodotti mediċinali inkluża l-insulina, meta dawn ma jipprovdux kontroll gliċemiku adegwat. fil-pazjenti li diġà qegħdin jiġu kkurati b'kumbinazzjoni ta canagliflozin u metformin bħala separati tabletsfor-riżultati tal-istudju fir-rigward tal-kombinazzjoni ta ' terapiji, l-effetti fuq il-kontroll gliċemiku u episodji kardjovaskulari, u l-popolazzjonijiet studjati, ara sezzjonijiet 4. 4, 4. 5 u 5.
brinavess
correvio - vernakalant hydrochloride - fibrilazzjoni atrijali - terapija kardijaka - konverżjoni mgħaġġla tal-bidu reċenti fibrillazzjoni atrijali għal sinus rhythm fl-adulti:għall-non-kirurġija il-pazjenti: fibrillazzjoni atrijali .
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doxorubicin hydrochloride - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - aġenti antineoplastiċi - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
sibnayal
advicenne s.a. - potassium citrate monohydrated, potassium hydrogen carbonate - acidosis, renal tubular - mineral supplements - sibnayal is indicated for the treatment of distal renal tubular acidosis (drta) in adults, adolescents and children aged one year and older.
tacforius
teva b.v. - tacrolimus monohydrate - liver transplantation; kidney transplantation - immunosoppressanti - profilassi tar-rifjut tat-trapjanti f'riċevituri ta 'l-alloġib tal-kliewi jew tal-fwied adulti. kura ta 'rifjut tal-allograft reżistenti għat-trattament ma' prodotti mediċinali immunosoppressivi oħra f'pazjenti adulti.
tookad
steba biotech s.a - padeliporfin di-potassium - neoplasmi prostatiċi - aġenti antineoplastiċi - tookad huwa indikat bħala monoterapija għall-pazjenti adulti li ma ġietx ikkurata qabel, unilaterali, riskju baxx, l-adenokarċinoma tal-prostata bil-għomor tal-ħajja ≥ 10 snin u:kliniċi stadju t1c jew t2a;gleason score ≤ 6, ibbażata fuq l-għolja tal-riżoluzzjoni tal-bijopsija l-istrateġiji;psa ≤ 10 ng/ml;3 pożittivi kanċer tal-cores b'massimu tal-kanċer tal-qalba it-tul ta '5 mm fil-ebda wieħed mill-qalba jew 1-2 pożittivi kanċer tal-cores ta' ≥ 50 % tal-kanċer l-involviment fl-ebda wieħed mill-qalba jew psa densità ≥ 0. 15 ng/ml/m3.
akynzeo
helsinn birex pharmaceuticals ltd - netupitant, palonosetron hydrochloride - vomiting; neoplasms; nausea; cancer - anti-emetiċi u anti-nawżjanti, - akynzeo huwa indikat fl-adulti għall -: il-prevenzjoni tal-akuta u ttardjata dardir u r-rimettar assoċjati mal ferm emetoġenika bbażata fuq cisplatin kimoterapija tal-kanċer. il-prevenzjoni ta akuta u ttardjata'nawseja u rimettar assoċjati ma'kimoterapija tal-kanċer moderatament emetoġenika.
eviplera
gilead sciences international ltd - emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - eviplera huwa indikat għall-kura ta ' adulti infettati bil-virus ta ' immunodefiċjenza umani tat-tip 1 (hiv-1) mingħajr mutazzjonijiet magħrufa assoċjati mal-reżistenza għall-klassi ta ' l-inibitur (nnrti) in-nuqqas ta ' nukleosidi rivers transcriptase, tenofovir jew emtricitabine, u mal-virali jillowdja ≤ 100,000 hiv-1 rna kopji/ml. bħal prodotti mediċinali antiretrovirali oħra, l-ittestjar tar-reżistenza ġenotipika u / jew id-dejta ta 'reżistenza storika għandhom jiggwidaw l-użu ta' eviplera.
lonsurf
les laboratoires servier - trifluridine, tipiracil hydrochloride - neoplażmi kolorettali - aġenti antineoplastiċi - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
xaluprine (previously mercaptopurine nova laboratories)
nova laboratories ireland limited - 6-mercaptopurine monohydrate - lewkimja, limfoma - aġenti antineoplastiċi - xaluprine huwa indikat għall-kura ta 'lewkimja limfoblastika akuta (all) f'adulti, adolexxenti u tfal.